Pramipexole Extended-Release: A Review of Its Use in Patients with Parkinson’s Disease

Abstract

Pramipexole, a non-ergolinic, D3-preferring dopamine agonist (DA), is well established as a treatment option for motor symptoms at all stages of Parkinson’s disease (PD). It is administered orally and is available as both a three-times daily immediate-release (IR) formulation and a once-daily extended-release (ER) formulation (Mirapex® ER, Mirapexin® ER… (More)
DOI: 10.1007/s40265-014-0322-5